XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53

Abstract The XPO1 inhibitor selinexor was recently approved in relapsed/refractory DLBCL patients but only demonstrated modest anti-DLBCL efficacy, prompting us to investigate the prognostic effect of XPO1 in DLBCL patients and the rational combination therapies in high-risk DLBCL. High XPO1 express...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Manman Deng, Mingzhi Zhang, Zijun Y. Xu-Monette, Lan V. Pham, Alexandar Tzankov, Carlo Visco, Xiaosheng Fang, Govind Bhagat, Feng Zhu, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, William W. L. Choi, Jooryung Huh, Maurilio Ponzoni, Andrés J. M. Ferreri, Michael B. Møller, Benjamin M. Parsons, J. Han van Krieken, Miguel A. Piris, Jane N. Winter, Fredrick Hagemeister, Lapo Alinari, Yong Li, Michael Andreeff, Bing Xu, Ken H. Young
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BMC 2020-11-01
Reeks:Journal of Hematology & Oncology
Onderwerpen:
XPO1
DLBCL
HGBCL
TP53 mutation
Selinexor
MYC
Online toegang:http://link.springer.com/article/10.1186/s13045-020-00982-3
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items